Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.

Author: HwangYong Il, JungJi Ye, JungKi-Suck, KimSong, KimTae-Hyung, LeeJi-Hyun, LeeSei Won, ParkHye Yun, ParkJeong-Woong, RheeChin Kook

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study highlights the need for alternative therapeutic approaches for patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic despite single bronchodilator therapy.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND">Long-acting bronchodilator monotherapy (long-acting &#946;<sub>2</sub>-agonist [LABA] or long-acting muscarinic antagonist [LAMA]) is extensively used for treatment of patients with chronic obstructive pulmonary disease (COPD) with mild-to-moderate airflow limitation. However, a s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322667/

データ提供：米国国立医学図書館（NLM）

Indacaterol/Glycopyrronium: A New Hope for COPD Patients

Chronic obstructive pulmonary disease (COPD), a condition characterized by airflow limitation, affects millions of people worldwide. Imagine a desert traveler struggling to breathe through a sandstorm, with each breath a laborious effort. This is a fitting analogy for individuals with COPD. This research focuses on the potential of a fixed-dose combination of indacaterol and glycopyrronium in managing symptoms of mild-to-moderate COPD. The authors recognize that a significant number of patients continue to experience symptoms despite treatment with a single bronchodilator, prompting the need for alternative therapies.

Finding a Path Through the Sandstorm of COPD

The study highlights the potential of indacaterol/glycopyrronium as a promising option for COPD patients who require a change in therapy. The researchers aim to evaluate the efficacy and safety of this combination in a randomized controlled trial. Imagine finding a new path through the desert, one that offers smoother terrain and a more comfortable journey. This is the hope that this study holds for those battling COPD.

Breathing Easier: Improving Quality of Life for COPD Patients

Improving the management of COPD can dramatically enhance quality of life. The study explores the potential of indacaterol/glycopyrronium to alleviate symptoms and improve lung function. This translates to better breathing, increased energy, and a more fulfilling life for those with COPD. Imagine the relief of a traveler finding a cool breeze in a scorching desert, allowing for easier breathing and a renewed sense of comfort.

Dr.Camel's Conclusion

This research offers a promising avenue for improving the management of COPD. The study explores the potential of a fixed-dose combination of indacaterol and glycopyrronium to provide relief for patients who continue to experience symptoms. Navigating the challenges of COPD can be daunting, but this research offers a ray of hope, much like a desert traveler finding a source of water amidst the arid landscape.

Date :
  1. Date Completed 2018-02-26
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

28228162

DOI: Digital Object Identifier

PMC5322667

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.